The ability of agonists to reduce these measures of tumor aggression is consistent with previous studies, for example, from Safe et al. [213,214,215] and Kolluri et al. [210,216], showing that AHR hyper-activation with agonists can be anti-tumorigenic. The gene discussed is AHR; the disease is neoplasm.